Personalized Cancer Vaccine Proves Promising in a Phase 1 Trial at Mount Sinai
New York, NY, March 21, 2025 (GLOBE NEWSWIRE) — Key Findings: This study demonstrates that tailored vaccines targeting patient-specific neoantigens (proteins that can trigger an immune response against cancer) can generate a potent immune response, with early data suggesting a correlation with improved long-term survival. A personalized multi-peptide neoantigen cancer vaccine called PGV001, using relatively […]